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ABSTRACT
Cardiac dysfunction is commonly associated with high-blood-pressure-
induced cardiomyocyte hypertrophy, in response to aberrant renin-
angiotensin system (RAS) activity. Ensuing pathological remodelling
promotes cardiomyocyte death and cardiac fibroblast activation, leading
to cardiac fibrosis. The initiating cellular mechanisms that underlie this
progressive disease are poorly understood. We previously reported a
conditionalmousemodel inwhichahumanangiotensin II type-I receptor
transgene (HART) was expressed in differentiated cardiomyocytes after
they had fully matured, but not during development. Twelve-month-old
HART mice exhibited ventricular dysfunction and cardiomyocyte
hypertrophy with interstitial fibrosis following full receptor stimulation,
without affecting blood pressure. Here, we show that chronic HART
activity in young adult mice causes ventricular dysfunction without
hypertrophy, fibrosis or cardiomyocyte death. Dysfunction correlated
with reduced expression of pro-hypertrophy markers and increased
expression of pro-angiogenic markers in the cardiomyocytes
experiencing increased receptor load. This stimulates responsive
changes in closely associated non-myocyte cells, including the
downregulation of pro-angiogenic genes, a dampened inflammatory
response and upregulation of Tgfβ. Importantly, this state of
compensated dysfunction was reversible. Furthermore, increased
stimulation of the receptors on the cardiomyocytes caused a switch in
the secondary response from the non-myocyte cells. Progressive
cardiac remodelling was stimulated through hypertrophy and death of
individual cardiomyocytes, with infiltration, proliferation and activation of
fibroblast and inflammatory cells, leading to increased angiogenic and
inflammatory signalling. Together, thesedata demonstrate that a state of
pre-hypertrophic compensated dysfunction can exist in affected
individuals before common markers of heart disease are detectable.
The data also suggest that there is an initial response from the
housekeeping cells of the heart to signals emanating from distressed
neighbouring cardiomyocytes to suppress those changes most
commonly associated with progressive heart disease. We suggest that
the reversible nature of this state of compensated dysfunction presents
an ideal window of opportunity for personalised therapeutic intervention.
KEY WORDS: Renin angiotensin system, Conditional transgenic
mouse, Cardiac hypertrophy, Fibrosis, Dysfunction, Remodelling
INTRODUCTION
Heart failure is a progressive condition defined by cellular and
molecular abnormalities that lead to pathological remodelling, a key
feature of which is cardiomyocyte (CM) hypertrophy (Katz, 1994,
2003). Cardiac hypertrophy is characterised by CM loss,
proliferation of cardiac fibroblasts, and collagen deposition
(Braunwald and Bristow, 2000; Frey and Olson, 2003), leading to
interstitial fibrosis with stiffening of the ventricles and impaired
contractile function (Shirwany and Weber, 2006; Weber, 2005).
Although various triggers have been identified (Braunwald and
Bristow, 2000; Frey and Olson, 2003), the mechanism behind
switching from normal state to hypertrophy and remodelling
remains enigmatic. Of particular interest is the renin-angiotensin
system (RAS). Angiotensin II (AngII), the major active component
of RAS, is responsible for regulating arterial blood pressure, plasma
volume and sympathetic nervous activity, and can also promote
growth and proliferation through activation of signalling
mechanisms (Berry et al., 2001; Frey and Olson, 2003; Levy,
2005; Oro et al., 2007) primarily through the type-1 receptor
(AT1R).
RAS activity is involved in heart failure beyond its influence on
blood pressure, because selective blockade attenuates hypertrophy
(Barrios et al., 2007; Okin et al., 2003). Furthermore, AT1R can be
stimulated locally (Zou et al., 2004) and could thus promote
localised growth. Owing to the ubiquitous nature of RAS,
separating systemic from localized activity has been difficult.
Previously, we reported a novel model of heart disease that is highly
controllable, the human angiotensin receptor transgenic (HART)
mouse, in which in utero effects of receptor stimulation are avoided
and expression is induced in adulthood (Ainscough et al., 2009). In
the unstimulated state the transgenic receptors exhibit low-level
activity confined to CM cells, whereas stimulation with the AngII
byproduct, AngIV, confers full activity. Twelve-month-old HART
mice developed cardiac hypertrophy without fibrosis under
unstimulated conditions, whereas stimulation with AngIV for
4 weeks exacerbated the hypertrophic response and induced
fibrosis. Hearts from these aged HART mice also exhibited
dilatation with reduced ejection fraction. Importantly, these
changes occurred in the absence of changes in blood pressure. We
therefore hypothesized that this controllable model of cardiac
remodelling is uniquely suited to dissecting early progressive
changes before the onset of hypertrophy and initiation of fibrosis.
Here, we have identified and characterised a previously
unreported state of heart failure prior to the development of
hypertrophy, which we term pre-hypertrophic compensated heart
failure. We utilised our HART model to investigate initiating events
in young adult mice, with and without stimulation of CM-specific
receptors by AngIV. Our results demonstrate that AT1R activity
drives CM dysfunction prior to hypertrophy or fixed myocardialReceived 14 November 2014; Accepted 26 May 2015
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remodelling. Furthermore, we show that this correlates with
enhanced CM-specific pro-angiogenic gene expression, and a
concomitant and more significant decrease from the non-myocyte
(NM) population. Changes occurring in the CM population were
associated with a responsive wave of changes in the NM population
of the heart, primarily downregulation of inflammatory markers and
upregulation of Tgfβ. Subsequent stimulation of the receptors with
AngIV resulted in further cardiac dysfunction, CM hypertrophy,
and initiation of fibrosis. This step change in the remodelling
process correlated with further (albeit subtle) changes in both
CM and NM populations, notably increased inflammatory markers
from NM cells. At no time during the switch from ‘normal’ to
‘compensated’ and then to ‘progressive’ remodelling did we detect
significant alterations in collagen, expressed exclusively by the NM
population. This investigation therefore unveils a complex interplay
between different cellular compartments of the heart during very
early initiating events of pathological remodelling in response to
CM-specific AT1R-induced cellular dysfunction.
RESULTS
The primary reason for this study was to investigate the initiating
mechanisms and complex interplay between different cell types of
the heart that occur during the earliest stages of progressive heart
disease, with a view to revealing accessible targets for development
of novel therapeutics. We have used the HART activation system in
5-month-old males to relate phenotypic changes that occur during
the switch from normal to remodelling state with changes in gene
expression specific to the CM and NM populations of the heart.
HART activity induces a reversible state of pre-hypertrophic
compensated dysfunction
Five-month-old wild-type (WT) and transgenic (Tg) HART mice,
in which AT1R was overexpressed exclusively in differentiated CM
cells, were analysed by Millar catheter. Ejection fraction (EF) was
significantly decreased in Tg compared to WT mice (Table 1,
Fig. 1A), whereas end systolic volume (eSV) and end diastolic
volume (eDV) were increased (Table 1, Fig. 1B,C). When HART
mice were reintroduced Dox at 4 months, to block production of
new transgenic receptors, Millar catheter analysis showed
significant improvement in ventricular function, approaching WT
levels (Table 1, Fig. 1A-C). After 8 weeks of Dox treatment
(Table 1, Group G), EF, eSV and eDV were indistinguishable from
normal (Group A). In contrast, 4 weeks of AngIV treatment caused a
further decrease in EF compared to WT and Tg groups, correlating
with a significant increase in eSV and eDV, indicative of ventricular
dysfunction and dilatation (Table 1, Fig. 1A-C). Previously we
showed that the dose of AngIV that is infused does not influence
blood pressure (Ainscough et al., 2009). As expected, this dose also
had no impact on EF in WT mice (Table 1, Group H). It did,
however, cause a notable increase in eDV, suggesting a dynamic
role to regulate blood supply that is within normal physiological
parameters. We also investigated morphological indicators of
ventricular hypertrophy. Cardiac weight index (CWI) remained
unchanged betweenWT and Tg animals, but significantly increased
after AngIV treatment (Fig. 1D). Consistent with this, CM cross-
sectional area was increased only after AngIV treatment (Fig. 1E).
We next looked for evidence of fibrosis. Previously we showed
that, in addition to labelling of cell membranes, wheat germ
agglutinin (WGA) can efficiently detect very small regions of
developing fibrosis (Ainscough et al., 2009). Conventional staining
techniques were less reliable unless the fibrotic lesions were
advanced. No major fibrotic lesions were observed in either WT or
Tg hearts (Fig. 2A). We also detected minimal evidence, in either
WT or Tg hearts, for cell turnover modulated by apoptosis and/or
necrosis, using TUNEL as a marker of DNA fragmentation
(Fig. 2A). Rare TUNEL-positive cells observed in both WT and
Tg hearts were confined to the NM population (Fig. 2B).
Immunostaining for cleaved caspase-3 as a secondary marker of
cell death confirmed these findings, with no evidence for positive
staining in either WT or Tg myocardium (supplementary material
Fig. S1). In contrast to WT and Tg animals, WGA staining of Tg
hearts after AngIV infusion revealed sporadic fibrotic lesions within
the left ventricle, with induction of CM cell death (Fig. 2C) in
addition to NM cell death (Fig. 2D) in otherwise healthy regions of
the Tg myocardium. TUNEL signal was evident in approximately
0.4% of the CM population, whereas cell death in the NM
population increased over threefold (Fig. 2B). However, no
evidence was observed for induction of cleaved caspase-3 in these
hearts (supplementary material Fig. S1).
Consistent with the CWI, fibrosis, TUNEL and cleaved caspase-3
data, no changewas detected in the relative proportion of NM to CM
TRANSLATIONAL IMPACT
Clinical issue
Poor heart function (heart failure) is usually associated with enlargement
of heart muscle cells induced by high blood pressure, in response to
altered renin-angiotensin system (RAS) activity throughout the body.
Subsequent complications include the death of heart muscle cells and
increased production and activation of fibroblasts resulting in fibrosis,
stiffening, and worsening ability for the heart to pump effectively.
Increasing evidence suggests, however, that RAS activity within
individual heart muscle cells plays a direct role in this process,
independent of blood pressure, but this has been very difficult to
resolve. Consequently, the blood-pressure-independent mechanisms
that regulate the early stages of heart failure remain unknown. A better
understanding of these mechanisms would facilitate development of
personalised treatments against this debilitating disease.
Results
Here, the authors use a transgenic mouse model to investigate the
initiating stages of heart failure. In the model, expression of a human
angiotensin II type-I receptor transgene (HART) is turned on in heart
muscle cells after they have fully formed. At 5 months old, the hearts of
HART mice have reduced pumping ability without muscle cell
enlargement or death, or fibroblast activation. Importantly, this stage is
completely reversible simply by inhibiting the production of the
angiotensin receptors. Reduced heart function in the HART mice
correlates with reduced expression in heart muscle cells of genes
involved in the regulation of blood pressure, salt level, calcium handling
and mitochondrial function. Moreover, other cells of the heart show
suppression of genes involved in the production of newblood vessels and
in inflammatory responses. Further activation of the receptors, however,
causes enlargement and sporadic death of the heart muscle cells, with
increased production and activation of fibroblasts and inflammation-
associated cells, signalling onset of progressive deterioration.
Implications and future directions
This study identifies a state of compensated heart dysfunction that
occurs in response to increased RAS activity within individual heart
muscle cells. The condition seems to be remarkably stable and, more
importantly, treatable with RAS inhibitors, before any long-term damage
is initiated. An appropriate screening procedure could be adopted,
therefore, to identify ‘at risk’ patients with reduced heart function but no
other signs of progressive heart disease. A personalised treatment
regimen for these patients with available RAS inhibitors, and regular
monitoring of heart function, might prevent the progressive stages of
heart failure occurring by intervening before the disease has had the
chance to properly take hold.
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cells, with both WT and Tg hearts exhibiting between 35-40% NM
cells per 0.5 µm section depth (Fig. 3A). Moreover, the AngIV-
treated group showed evidence for increased NM proliferation (most
likely fibroblasts and/or inflammatory cells), seen as clusters of NM
nuclei interspersed between groups of CM cells (Fig. 3A). It is
worth noting that CM cells are approximately 5-10× longer than
NM cells (∼100 µm cf. 10-20 µm); thus, the ratio of NM:CM cells
reported here likely under represents the true situation (Fig. 3B).
We next looked for evidence of increased inflammation that
might correlate with the observed dysfunction, using the
macrophage-specific marker CD68 (Fig. 4). Whereas no CD68-
positive cells were detected in WT hearts, sporadic individual
positive cells were observed in Tg hearts at a low frequency
(Fig. 4A,B,E). In contrast, AngIV treatment led to a significant
increase in macrophage number, exclusively clustered in regions
undergoing fibrotic remodelling (Fig. 4C,E). To assess the extent of
AngIV-induced remodelling, we subjected a further cohort to
treatment with AngII, which stimulates AT1 receptors in all cells
(not just CM) and induces pressure overload (Table 1). This caused
more extensive fibrosis (not shown), with Millar catheter analyses
indicating more severe heart failure as evidenced by reduced
EF (Table 1). AngII-treated myocardium showed evidence of
significant macrophage infiltration clustered within zones of
remodelling similar to that in the AngIV group (Fig. 4D,E).
Together, these data suggest that low-level chronic AT1 receptor
activity on CM cells, without stimulating receptors on other cell
types of the heart, is sufficient to cause cardiac dysfunction without
fibrosis or induction of a significant inflammatory or apoptotic
response. Increased stimulation leads to initiation of sporadic cell
death and associated macrophage infiltration. We conclude that the
observed cardiac dysfunction is a stable pre-hypertrophic
compensated state (PHCS) that is intrinsic to the CM itself, driven
directly via low-level signalling from the HART receptors.
Importantly, the data shows that cardiac dysfunction during PHCS
is reversible and represents an ideal opportunity for therapeutic
intervention.
To provide a clearer understanding of how these changes promote
the path towards heart failure, we next investigated changes that
occur in the CM cells, and secondary responses to these changes in
NM cells, separately.
AngIV modulation of genes associated with late-stage
cardiac remodelling
To investigate the mechanisms and cellular origin behind the
observed dysfunction followed by induction of cardiac enlargement
and fibrosis, we isolated two populations of cells from 5-month-old
hearts: (i) CM and (ii) NM (fibroblasts, vascular and inflammatory
cells). Rigorous assessment of cell fraction purity by both
microscopy and molecular analyses demonstrated that the CM
fraction was almost completely clear of NM contamination, whereas
the NM fraction routinely contained a low level of contaminating
CM cells (see Materials and Methods, and supplementary material
Fig. S2). The transcription factor GATA4 was expressed at similar
levels in both fractions, whereas CM-specific αMHC levels were
Table 1. Assessment of cardiac function
Parameter
(A) WT
(n=13)
(B) Tg
(n=5)
(C) Tg/saline
(n=6)
(D) Tg/AngIV
(n=8)
(E) Tg/AngII
(n=8)
(F) Tg/1 mo
DOX (n=8)
(G) Tg/2 mo DOX
(n=5)
(H) WT/AngIV
(n=6)
BP 88.38±1.51 86.4±1.72 84±4.65 81.7±3.98 102.68±5.53
(A**, B*, C*, D**)
78.87±2.53 (A**) 74.9±3.21
(A***, B*)
85.33±2.37
Heart rate
(beats/min)
582.61±17.04 566.2±12.9 584±38.6 488±28.83 (A**) 567.87±15.72 (D*) 581.62±18.32 (D*) 570.4±21.48 605.33±26.94
End systolic volume
(µl)
7.14±1.3 15.82±2.95 (A**) 13.82±2.03 (A*) 21.96±2.18
(A***, C*)
21.11±2.58 (A***) 13.38±1.04
(A**, D**)
8.55±1.97
(D**, F*)
10.1±1.63
End diastolic volume
(µl)
19.87±1.37 26.37±4.06 24.47±1.53 34.30±3.21
(A***, C*)
27.46±3.49 (A*) 25.63±1.96
(A**, D*)
21.56±2.1 (D*) 28.26±2.7
End systolic
pressure (mmHg)
93.64±4.25 99.48±3.80 93.02±5.03 84.26±5.42 110.05±9.65 (D*) 97.99±4.86 91.03±6.37 93.49±4.42
End diastolic
pressure (mmHg)
8.04±1.07 9.54±1.85 7.26±1.82 10.47±1.94 7.51±1.74 7.21±1.60 5.70±0.76 4.67±0.61
Stroke volume
(µl)
15.54±0.89 13.73±0.55 13.12±2.06 14.86±1.81 9.44±1.68
(A**, D*)
16.87±0.97 (B*) 16.89±1.19 (B*) 21.83±1.29
Ejection fraction (%) 73.26±3.74 51.09±4.42 (A**) 50.77±7.28 (A**) 42.19±3.25
(A***)
32.28±4.59
(A***, B*)
60.35±3.02
(A*, D**)
71.1±4.09
(B*, C*, D***)
71.05±3.31
dPdT max
(mmHg/s)
9994±743.93 9814±859.82 9194.3±1153.39 7069±749.33
(B*)
8831.5±888.55
(A*)
10,394.75±633.32
(D**)
10,954.4±646.37
(D**)
11,811.5±915.58
dPdT min
(mmHg/min)
−9433.3±880.41 −8814.6±744.41 −8566.16±847.12 −6338.75±796.66
(A*)
−8277.5±773.47 −10,079.12±922.7
(D**)
−10,923±1127.9
(D**)
−13,450±1270.2
dVdT max
(µl/s)
1078.61±140.81 799±101.29 837±181.89 1071.62±125.12 898.62±133.47 948.25±122.31 737±44.30 833.5±49.01
dVdT min
(µl/s)
−875.6±87.15 −766±122.77 −780.33±164.35 −831.87±158.2 −803.5±147.25 −948.25±122.31
(A***, B***, C***,
D***)
−905.6±174.85
(F***)
−1411.67±210.17
Max power
(mWatt/µl2)
316.74±48.58 141.39±25.93 (A*) 149.3±36.19 (A*) 70.81±18.83
(A**, B*)
129.42±35.19 (A*) 169.71±22.32
(A*, D**)
224.83±38.66
(D**)
232.73±39.4
Stroke work
(mmHg/µl)
1332.61±107.67 1091±75.56 1062±220.18 993.62±146.77 871±207.94 (A*) 1408±133.51 1469±107.82
(B*, D*)
1986.5±168.24
Cardiac output
(µl/min)
9096.38±624.47 7768±316.01 7824.52±1619.29 7355.25±1074 5339.93±872.9
(A**)
9844.33±736.03 9604.09±696.62
(B*)
13,212.07±1017.74
Arterial elastance 6.24±0.42 7.32±0.48 8.03±1.26 6.51±1.15 (C**) 13.54±1.73
(A***, B*, D**)
5.99±0.51 5.54±0.61 4.34±0.22
Tau (Weiss) 6.08±0.68 5.55±1.01 4.78±0.88 7.50±1.34 6.64±0.77 5.43±0.49 4.66±0.25 4.17±0.79
Wild-type (WT) and transgenic mice, either untreated (Tg), or treated with saline (Tg/Saline), Ang IV (Tg/AngIV) or Ang II (Tg/AngII) for 4 weeks, or doxycycline for 1 month (Tg/1 mo DOX)
or 2 months (Tg/2 mo DOX)§, were subjected to Millar catheter analysis to assess cardiac function at 5 months (§6 months).
The data are presented as mean±s.e.m. Degree of significance between groups is indicated relative to group shown (*P≤0.05, **P≤0.01 or ***P≤0.001).
dPdT, pressure change/time; dVdT, volume change/time.
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high in the CM fraction and low in the NM fraction. This low level
of αMHC, most likely caused by inclusion of CM debris from
fragmented cells, was routinely used as a marker for purity
assessment. Gapdh was used as a control because its levels (CT
values relative to input cDNA) were consistent between CM and
NM populations, and between WT, Tg and Tg+AngIV samples. In
contrast, β-actin mRNA levels showed dramatic differences
between groups (not shown). Validated high-quality fractions
were then used to analyse expression profiles of key genes
commonly used as markers of ventricular fibrosis, hypertrophy
and angiogenesis (Fig. 5). Supplementary material Fig. S3 shows
the same expression data after adjustment to take account of the
relative contribution of CM and NM cells, as indicated in Fig. 3A.
Initially, we examined Col1α1, which is upregulated in cardiac
fibroblasts in response to myocardial damage. As expected, the
isolated CM fraction did not express Col1α1 (Fig. 5A). Importantly,
this confirmed that the cell fractionation method generated a pure
CM fraction with minimal NM contamination. In contrast, the NM
fraction expressed Col1α1 at high levels that were indistinguishable
between groups (Fig. 5A), although a small increase was noted after
AngIV treatment when relative cell contribution was taken into
consideration (supplementary material Fig. S3A). However, the lack
of significant increase in collagen indicates that this aspect does
not present until later in the progression towards pathological
remodelling. Similar to the Col1α1 profile, the CM population did
not express Tgfβ (Fig. 5B). However, the NM fraction showed a
progressive increase in Tgfβ in both the Tg and AngIV groups
(Fig. 5B, supplementary material Fig. S3A), suggesting that
increased Tgfβ production precedes collagen, consistent with
causative but delayed action in this respect. TGFβ has been
previously reported to promote synthesis of vascular endothelial
growth factor α (VEGFα) (Nakagawa et al., 2004). VEGFs are
essential regulators of vasculogenesis, angiogenesis and vessel
maintenance during embryonic development and adulthood
(Zentilin et al., 2010) that are known to be upregulated during
pathological remodelling to compensate for increased oxygen
demand. We found that CM and NM fractions expressed Vegfα at
similar levels in WT hearts (Fig. 5C, supplementary material Fig.
S3A). However, although a slight tendency towards increasing
Vegfα expression was detected in the CM population, the NM
Fig. 1. Ventricular dysfunction is observed in 5-month-old HART
mice prior to onset of hypertrophy or fibrosis. Stimulation with
AngIV for 4 weeks promotes hypertrophy with worsening ventricular
dysfunction, whereas inhibition of receptor expression improves
function. (A) Ejection fraction (%EF) of HART males (Tg) was
significantly reduced relative to wild-type littermate controls (WT).
Exposure to AngIV caused further reduction in EF, whereas Dox
treatment relieved the dysfunction. (B,C) End systolic volume (eSV)
and end diastolic volume (eDV) were significantly increased in Tg
males, and further increased following exposure to AngIV, consistent
with cardiac dilatation. Dox treatment reduced eSV and eDV to WT
levels within 8 weeks. (D) Cardiac weight index (CWI) for WT and Tg
mice showed no significant change, whereas AngIV treatment induced
a significant increase. (E) Representative fields of view of sectioned left
ventricle showing CM population in cross-section. Cell membranes
and ECM were detected with WGA, and nuclei with Hoechst 33342.
CM cross-sectional area was similar between WT and Tg mice, and
significantly increased following AngIV stimulation (n≥4 mice per
group, 5 fields of view per mouse). Scale bars: 20 µm. All data are
mean±s.e.m. Degree of significance between groups is indicated
(*P≤0.05, **P≤0.01, ***P≤0.001).
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population exhibited a reciprocal and more substantial downward
trend leading to a substantial differential between CM- and
NM-derived expression after AngIV treatment.
Pro-inflammatory genes are dynamically regulated in NM
cells of HART mice
Inflammation has been closely associated with heart disease (Shinde
and Frangogiannis, 2014; Turner, 2014), and CD68 staining used in
this study demonstrated significant macrophage infiltration in Tg
myocardium following AngIV stimulation, but not before. We
therefore analysed the inflammatory gene signature of the NM
population in WT mice, and in Tg mice before and after AngIV
treatment.
Tenascin-C (TNC) is associated with cellular injury and
inflammation, and has many cellular functions, with roles in
embryogenesis, wound healing and cancer progression (Imanaka-
Yoshida et al., 2004). Consistent with downregulation of Vegfα
from Tg NM cells, Tnc expression was also decreased (Fig. 5D,
supplementary material Fig. S3B). However, in contrast to Vegfα,
Tnc returned to WT levels following AngIV treatment. The pro-
inflammatory cytokines IL-6 and IL1-β were similarly decreased in
the Tg group, with only IL-6 returning to normal levels upon AngIV
stimulation (Fig. 5D, supplementary material Fig. S3B). The
chemokine Cxcl2 showed a similar profile, with a small initial
decrease in the Tg group that was reversed following AngIV
stimulation (Fig. 5D, supplementary material Fig. S3B).
Of particular note, all of the inflammation-associated genes
analysed were initially repressed in Tg animals that have cardiac
dysfunction without evidence of structural myocardial remodelling.
Even under conditions that lead to early stages of fibrosis and
macrophage infiltration, a substantial inflammatory response was
not initiated. The evidence therefore suggests that inflammatory
responses frequently associated with the remodelling process are
late-stage secondary responses. More importantly, our data suggest
Fig. 2. Stimulation with AngIV for 4 weeks induces cell
death in both CM and NM cells of 5-month-old HART mice,
promoting fibrosis.Representative images shown are stained
with WGA (green) to detect cell membranes and fibrotic
patches, TUNEL (red) to detect fragmenting DNA, and Hoechst
33342 (blue) to detect nuclei. (A) No difference in TUNEL
staining, either qualitative or quantitative, was detected
betweenWTand Tg hearts. Occasional positive nuclei (arrows)
were detected tightly embedded between CM cell membranes,
suggestive of NM status. No CM nuclei were observed to be
TUNEL positive. (B) Quantitative analysis of TUNEL data
expressed as % positive cells in CM, NM and total cell (T)
populations. The number of TUNEL-positive CM cells
increased from 0% to 0.4% with AngIV treatment, whereas
TUNEL-positive NM cells increased from 0.2% to 0.6%.
T increased from 0.2% (Tg) to 0.8% (AngIV), representing a
400% increase in total rate of cell death. (C) Representative
example of an AngIV-induced TUNEL-positive CM nucleus
(arrowhead) within a healthy region of the myocardium.
(D) After AngIV treatment, TUNEL-positive NM nuclei were
frequently observed in clusters embedded within areas of
developing fibrosis (arrow). Scale bars: 20 µm.
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that there is an initial inhibition of pro-inflammatory signalling from
the NM population in the presence of a functionally compromised
CM population, possibly in response to upregulation of TGFβ (van
Nieuwenhoven and Turner, 2013). This compensatory response is
reversed when the CM population is stressed to a critical level.
Differential expression of genes associated with CM
dysfunction
To get to the heart of initiating events driving CM dysfunction in
HART mice, rather than the frequently reported secondary
responses from other cell types in the myocardium, we
investigated CM-expressed genes that are commonly associated
with CM dysfunction. This includes activation of immediate early
genes (Lee et al., 1988), re-expression of foetal genes (Izumo et al.,
1988) and changes in expression of contractile and calcium
handling proteins (Braunwald and Bristow, 2000; Miyata et al.,
2000).
Upregulation of atrial natriuretic factor (ANF) is commonly used
as a marker for hypertrophy. ANF exhibits diuretic, natriuretic and
vasorelaxant effects and is responsible for maintaining blood
pressure and natriuresis (Lucas et al., 2010). ANF also reduces
fibrosis by inhibition of collagen synthesis from cardiac fibroblasts
(Redondo et al., 1998). Not unexpectedly in view of the observed
lack of CM hypertrophy, and consistent with the pattern seen for
pro-inflammatory genes in the NM fraction, Anf expression was
found to be significantly reduced in CM cells of the Tg group
(Fig. 5E). Following AngIV treatment, Anf levels remained low
(supplementary material Fig. S3C). Thus, ANF does not play a role
in induction of dysfunction in the HART model.
Recently, it has been suggested that, following activation of AT1R,
collagen can directly modulate the calcium dynamics and electrical
activities of atrial CM cells by increasing expression of the
sarcoplasmic reticular ATPase Serca2α and Thr17-phosphorylated
phospholamban, with no alteration in expression of Ryr2 (Lu et al.,
2011). In contrast, Serca2αwas shown to be downregulated in cardiac
hypertrophy, resulting in impaired diastolic and systolic function
(Houser and Margulies, 2003). Consistent with this, Iijima et al.
(1998) demonstrated that Serca2a is downregulated after myocardial
infarction, correlating with increased AT1R expression. Zentilin et al.
(2010) also found Serca2α, Ryr2 and Pgc1α to be significantly
decreased following myocardial infarction, accompanied by
hypertrophy and dysfunction. In our HART model, we found that
Serca2α levels dropped only slightly, whereas Ryr2 showed a more
substantial tendency to decrease (Fig. 5E, supplementary material
Fig. S3C). Taken together with the tendency towards reducing levels
of Vegfα driven mainly by the NM population, dysregulation of Ryr2
might play a part in initiation of CM dysfunction in our model.
Of greater interest, however, is PGC1α, a key regulator of
mitochondrial bioenergetics in the heart. Cardiac-specific repression
of PGC1α results in downregulation of mitochondrial enzymes,
morphological impairment and loss of mitochondria (Czubryt et al.,
2003). Furthermore, in chronic heart failure, PGC1α is downregulated
and correlates strongly with muscle oxidative capacity (Garnier et al.,
2003). We therefore examined whether the contractile dysfunction
observed in the Tg HART animals might be directly attributable to
modulation of PGC1α. Notably, expression was significantly
decreased in the Tg group, and further decreased following AngIV
treatment (Fig. 5E, supplementarymaterial Fig. S3C), suggesting that
compromised CM mitochondrial function might play a part in the
initiation of CM dysfunction. This warrants further detailed
investigation.
DISCUSSION
The RAS has been the subject of intense investigation for decades.
However, the full complexity and cell-type-specificity of its
involvement in initiating stages of heart disease remains
enigmatic. Although numerous studies have exploited alterations
in components of the RAS, none has yet clearly depicted initiating
events. Here, we have delineated stepwise progression of the earliest
stages using conditional transgenic HART mice, in which
Fig. 3. The ratio of CM:NMcells in healthy regions
of the heart changes in response to AngIV
treatment. (A) The proportion of NM cells in healthy
regions was increased in Tg hearts following AngIV
treatment. The image shows, additionally, that small
clusters of NM cells congregate within areas of
developing fibrosis in ‘unhealthy’ regions of the
myocardium. Scale bar: 20 µm. (B) Schematic
representation depicting (blue line) the area of
‘visibility’ within each section image in relation to the
three-dimensional structure of the myocardium.
The number of nuclei detected is a vast under-
representation of the true number of cells; thus, the
ratio presented in panel A effectively under-
represents the number of NM cells by approximately
five- to ten-fold.
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expression of a human AT1R is activated exclusively in fully
differentiated adult CM cells, with no changes in blood pressure.
Our data show that cardiac hypertrophy does not develop initially;
rather, cardiac dysfunction is a prominent initiating event. It is
noteworthy that even in a state of dysfunction the different cellular
compartments of the heart apparently interact to prevent
hypertrophic, inflammatory or angiogenic responses. Thus, we
have referred to this condition as a pre-hypertrophic compensated
state (PHCS) that is remarkably stable and reversible (Fig. 6).
Upon further stimulation of the receptor, without blood pressure
change, dysfunction is amplified, CM cells become hypertrophic
and sporadic fibrosis ensues. Once this process commences it
becomes very difficult to separate cause from consequence. The
results are consistent with a previously reported model of AT1R
overexpression that displayed CM hypertrophy with enhanced
collagen deposition, myolysis and cardiac remodelling (Paradis
et al., 2000). At 6 months of age, these mice were reported to exhibit
cardiac hypertrophy and ventricular contractile dysfunction (Rivard
et al., 2008). However, in young adults there was no evidence of
hypertrophy, but the CM cells exhibited both decreased fractional
shortening and contractility underlying the dysfunction (Rivard
et al., 2011). A further study was reported in which AT1Rs were
overexpressed in CM cells on an AngII-null background (Yasuda
et al., 2012). Constitutive AT1R activity was found to contribute to
progressive cardiac dysfunction and remodelling without AngII
stimulation. This is consistent with reports that the AT1R can exhibit
spontaneous activity, through utilisation of the receptor’s potential
energy (Karnik and Unal, 2012; Parnot et al., 2002). Taken together,
the data show that increased AT1R activity in CM cells will have
serious detrimental consequences if left unchecked.
Whole heart enlargement is primarily caused by hypertrophyof pre-
existingCMcells. In progressive heart disease, aswell as during natural
Fig. 4. Stimulation with AngIV for 4 weeks promotes
macrophage infiltration. Representative images shown are
stained with WGA (red) to detect cell membranes and fibrotic
patches, CD68 (green) to detect macrophages, and DAPI (blue)
to detect cell nuclei. (A) No CD68-positive cells were detected in
WT hearts. (B) Sporadic single positive cells were detected in
Tg hearts, but were not significantly different to WT.
(C) Treatment with AngIV resulted in an increased number of
CD68-positive cell clusters embedded within areas of
developing fibrosis (arrow). This was comparable to HART
hearts treated with AngII (D), which exhibited more fibrosis.
As expected, the only positive cells were detected tightly
embedded between CM cell membranes. Scale bars: 20 µm.
(E) Quantitation of CD68 data presented as % positive cells in
‘healthy’ and ‘remodelling’ areas of myocardium. Macrophages
were only observed in regions undergoing initiation of
remodelling. The proportion of ‘remodelling’ myocardium was
increased in Tg hearts after AngIV andAngII treatment, but were
still low at the level of the whole myocardium. Degree of
significance between groups is indicated (*P≤0.05; **P≤0.01;
ns, not significant).
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Fig. 5. Remodelling-associated
genes are differentially expressed in
CM and NM cells, with and without
stimulation with AngIV. (A) Col1α1
was not expressed in CM cells of any
group, whereas NM cells expressed
Col1α1 at similar levels in all groups.
(B) Tgfβ was also not expressed in CM
cells from any group. However, NM cells
from Tg mice showed increased Tgfβ,
with further increase upon AngIV
treatment. (C) Vegfα was expressed in
both CM and NM cells of all groups.
Tg CM cells expressed Vegfα at higher
levels thanWT CM cells, with additional
increase upon stimulation with AngIV.
Conversely, Vegfα expression from NM
cells was reduced in Tg animals, and
further reduced upon AngIV treatment.
(D) Pro-inflammatory gene expression
signature is dampened in Tg NM cells,
but begins to increase upon treatment
with AngIV. Expression of the
inflammatory marker Tnc was
significantly decreased in Tg NM cells,
but returned to normal levels following
AngIV treatment. The pro-inflammatory
cytokine IL-6 was also reduced in Tg
NM cells, and significantly increased on
exposure to AngIV. IL-1β followed a
similar profile to IL6, albeit less
pronounced, whereas the pro-
inflammatory chemokine Cxcl2 was
expressed at similar levels inWTand Tg
NM cells, and increased upon AngIV
treatment. (E) Differential expression of
CM-specific genes commonly
associated with cardiac dysfunction.
Anf expression was significantly
decreased in the Tg CM population and
increased upon treatment with Ang IV.
Serca2α, Ryr2 and Pgc1α showed a
tendency to decrease in Tg CM cells.
This response was enhanced upon
AngIV treatment. Degree of significance
between groups is indicated (*P≤0.05,
**P≤0.01).
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aging, the rate ofCMdeath increases and, as a compensatory response,
CM hypertrophy is initiated (Nadal-Ginard et al., 2003). Two distinct
mechanisms lead to cell death: apoptosis and/or oncosis. During
apoptosis the cell shrinks and is removed by neighbouring cells
with limited influence on tissue morphology and without collagen
accumulation. In contrast, oncosis is accompanied by an inflammatory
response, vessel proliferation, macrophage infiltration and fibroblast
activation leading to collagen deposition and scar formation (Nadal-
Ginard et al., 2003). Even a moderate rate of CM death can gradually
lead to a reduction in myocardial mass and result in chronic heart
failure. In our model, cell death was observed in the heart under
conditions where the transgenic receptor was unstimulated. Notably,
death was limited to the NM population and was actually associated
with downregulation of inflammation-associated genes, suggesting
that regulated apoptosis is responsible for natural turnover of NMcells.
IL-6 has been correlated with increased risk of LVH, dilatation,
dysfunction and fibrosis (Birner et al., 2007; Yan et al., 2010), so
reduced expression in the dysfunctional heart strongly supports an
active attempt to limit pathological remodelling. TNCshowed a similar
reduction in expression. This pro-angiogenic molecule (Ballard et al.,
2006) is upregulated in many pathological conditions, including
myocardial infarction, myocarditis, hibernating myocardium and
dilated NC cardiomyopathy (Imanaka-Yoshida et al., 2001;
Sato et al., 2002; Tamura et al., 1996). It has also been reported to
modulate proliferation and migration (Stepp and Zhu, 1997;
Yoshimura et al., 1999), playing an important role in wound healing
(Tamaoki et al., 2005).
Following stimulation with AngIV, the rate of cell death in the NM
population increased, CM death was also observed, and expression of
inflammatory markers began to increase. Although none of the genes
tested were expressed aboveWT levels, it is possible that this renewed
expression was highly focussed within areas of remodelling. The
changes coincided with infiltration by macrophages, suggesting that
stimulation of an inflammatory response might be in response to CM
oncosis rather than apoptosis. However, it remains undetermined
whether the macrophage infiltrates occurred in response to dying CM
cells, or to the increased rate of NM cell turnover. Indeed,
macrophages were generally only observed in areas of significant
fibroblast accumulation, and not around isolated CMs in healthy areas
of the myocardium, suggesting that progressive infiltration and
accumulation might be exacerbated by events occurring at sites
populated by NM cells. In any event, it was notable that little
difference was detected in Col1α1 at any stage, suggesting that the
changes observed reflect early events that precede progressive cardiac
remodelling. This is entirely consistent with the observed ability for
the heart to recover function upon suppression of HART expression,
demonstrating a ‘window of opportunity’ for successful treatment of
cardiac dysfunction by suppression of local RAS activity, prior to
induction of pathological remodelling (Fig. 6).
In contrast to all other genes tested, Tgfβ expression was
upregulated in NM cells at the earliest stages of remodelling. This
complex signalling molecule has been reported to possess anti-
inflammatory and anti-proliferative activity (Redondo et al., 2012),
which is consistent with our observations in the unstimulated
Fig. 6. Summary schematic of stepwise
progression of heart disease in
response to CM-specific AT1R activity.
From left to right: normal pathology and
function are indicated in green;
compromised function and pathological
remodelling are indicated in red. Basal
HART expression causes CM dysfunction
with no impact on pathology; this
dysfunction is associated with
compromised mitochondria and an attempt
to increase angiogenic signalling from the
distressed CM cells. This correlates with
dampened expression of pro-inflammatory
and angiogenic genes from the NM
population, leading to a reversible ‘pre-
hypertrophy compensated state’ (PHCS).
Treatment with AngIV, however, rapidly
induces CM hypertrophy and sporadic cell
death leading to state reversal, activation of
cardiac fibroblasts, macrophage infiltration
and a further decrease in angiogenic
response. This rapidly leads to
uncontrolled cell turnover in the NM
population, driving interstitial fibrosis and
ultimately heart failure. PHCS represents
an ideal state for therapeutic intervention.
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Tg hearts. However, inhibition of Tgfβ signalling in the pressure
overloaded heart has also been found to attenuate myofibroblast
proliferation and collagen deposition (Lucas et al., 2010). Our
observation of an increase in proportion of NM cells relative to CM
cells following AngIV stimulation supports a pro-proliferative role in
this context.
An increase in CM-specific Vegfα expression was detected in
transgenic animals both with andwithout AngIV treatment. However,
there was a responsive decrease in the NM cells consistent with a
secondary response to rebalance the level of pro-angiogenic gene
expression within the myocardium. VEGFs have been previously
shown to induce a gene expression programme consistent with
compensatory cardiac hypertrophy, by elevation of Anf, Bnp, αMHC,
Serca-2α, Ryr2 and Pgc1α, and by inhibition of βMHC and skeletal
alpha-actin (sk α-act) (Zentilin et al., 2010). In HART mice,
expression of Anf, Ryr2 and Pgc1α were observed to decline in the
CM population. This is not surprising given the significant reduction
in Vegfα expression from the HARTNMpopulation. We suggest that
the HART model represents a very early stage of pre-hypertrophy in
which VEGF signalling has not stabilized, the decrease in the NM
population representing an initial mechanism to prevent fibrosis by
inhibition of extracellularmatrix. It has been previously suggested that
VEGF is an essential mediator of AngII-induced vascular
inflammation and remodelling, but is not involved in AngII-induced
cardiac hypertrophy (Zhao et al., 2004).Ourobservation of a tendency
towards increased macrophage infiltration and sporadic fibrosis in
HART mice following AngIV treatment, at a time when Vegfα
expression is further suppressed from the NM population, suggests
that VEGFα is not a principal mediator of this response.
Upon activation of the intracellular CM RAS by AngIV,
dysfunction and dilatation were intensified, leading to hypertrophy,
increased cell death, macrophage infiltration and sporadic fibrosis.
The results are consistentwith an early transition out of a compensated
pre-hypertrophic state towards fixed pathological remodelling. We
suggest that alterations in mitochondrial energetics might represent a
suitable therapeutic target that warrants detailed investigation.
MATERIALS AND METHODS
HART mouse model
Animal work was carried out with ethical approval (University of Leeds,
UK) under UK Home Office licence. The study utilised male HART mice
that in adulthood express a constitutively active mutant form of human
AT1R in differentiated cardiomyocytes, through action of a cell-type-
specific tetracycline transactivator (Ainscough et al., 2009). The
experiments thus utilised double-transgenic (Tg) animals that harboured
both hAT1R-lacZ responder and αMHC-tTA activator transgenes (Tg group),
as well as sex- and aged-matched wild-type littermate controls (WT group).
WT mice harboured either transgene independently, or neither transgene.
The mice were bred on Dox (125 μg/ml) and weaned onto normal drinking
water at 1 month. Previous results showed that HART is maximally activated
within 2 weeks of Dox withdrawal, and high-level expression continues into
adulthood. All mice were analysed at 5 months, unless otherwise stated.
Some transgenic animals (Tg) were infused with AngIV continuously at
5 µg/kg body weight/min for 4 weeks via a subcutaneously implanted
miniosmotic pump. WT mice were used as controls against Tg mice,
whereas Tg and Tg mice treated with saline for 4 weeks were used as
controls against Tg mice treated with AngIV for 4 weeks. No significant
differences were observed between Tg and Tg-saline mice.
Ventricular function
Millar catheter analysis was performed as previously described (Ainscough
et al., 2009). Briefly, mice were anaesthetised with isoflurane and the right
carotid artery exposed. A 1.4 F miniature pressure-volume catheter (SPR-
839, Millar Instruments, USA) was inserted through the right carotid artery
into the ascending aorta and then into the left ventricle via the aortic valves.
This was connected to an MPVS-300 (Millar Instruments) and data were
recorded using AD instruments Chart software (Chart 5 Pro). PV loop
analysis was performed using PVAN 3.6.
Cardiac weight index (CWI)
Body weight was recorded, then the heart removed and cleaned with ice-
cold PBS. Atria were removed and assayed for lacZ activity to confirm
genotype (Ainscough et al., 2009). The ventricles were cleared of blood,
blotted, weighed and snap-frozen in liquid nitrogen. Tibia were also
removed, cleaned and measured. Ventricular weight to tibia length ratio
(mg/mm) was recorded as CWI. Ventricle to body weight ratio (mg/g) was
also determined.
Cardiac-cell isolation
CM and NM cells were separated into fractions using a modified
Langendorff apparatus. All buffers were pre-warmed to 37°C unless
otherwise stated. Males were euthanized, hearts excised, cannulated via the
aorta onto a Langendorff apparatus, and perfused with dissociation buffer
(130 mM NaCl, 5 mM KCl, 25 mM Hepes, 0.5 mM MgCl2, 0.33 mM
monobasic NaH2PO4, 22 mM D-glucose, 3 mM Na pyruvate) containing
100 mM EGTA until cleared of residual blood. The heart was then perfused
with 25 ml dissociation buffer containing 144 U/ml collagenase
(Worthington type-2) and 50 µM CaCl2. The ventricles were placed in
12.5 ml dissociation buffer supplemented with 144 U/ml collagenase,
100 µM CaCl2, 1% BSA at room temperature, cut into small pieces and
gently agitated by repeat pipetting. The cell suspension was filtered through
nylon gauze to remove remaining tissue clumps, then processed for isolation
of cardiomyocyte (CM) and non-myocyte (NM) fractions. A loose CM
pellet was first settled by gravity, then washed in 10-ml ice-cold digestion
buffer containing 250 µM CaCl2 and 1% BSA.
RNA extraction, cDNA synthesis and qPCR
For RNA isolation, CM cells were further purified away from remaining NM
cells by gentle resuspension and centrifugation in ice-cold PBS (3×1 min) at
500 rpm at 4°C, then resuspended in 1 ml TRI-reagent (Ambion, UK). The
remaining NM-cell-containing supernatant from the initial CM settling was
further cleared of CM cells by sequential centrifugation (4×1 min) at
500 rpm at 4°C until no CM pellet was visible. The remaining supernatant
was centrifuged at 1500 rpm for 10 min to pellet the NM population, which
was resuspended in TRI-reagent for RNA isolation following the
manufacturer’s instructions. For whole heart RNA, ten 30-µm cryo-
sections were cut using a Leica cryostat, homogenised in 1 ml TRI-
reagent, then processed as before. All RNA samples were treated with
TURBO DNase (Ambion, UK) and reverse transcribed into cDNA with
Superscript III (Invitrogen, UK) using random hexamers (Sigma). For qPCR
analysis, cDNAs were added to reactions containing Taqman PCR master
mix, gene-specific primer-probe sets for Col1α1, Tgfβ, Vegfα, Tnc, IL-6,
IL-1β,Cxcl-2, Anf, Serca2α, Ryr2, Pgc1α andGapdh (Applied Biosystems),
and amplified using an ABI-7500-PCR system. All samples were
normalised to Gapdh. Relative expression was calculated as 2−ΔCT×100
and presented as % Gapdh.
Histology for cell counts and macrophage infiltration
10-µm heart cryo-sections were mounted on poly-L-lysine-coated slides and
fixed with 4% paraformaldehyde for 20 min, washed with PBS, incubated
with rhodamine-linked wheat germ agglutinin (WGA; 1:1000; Vector
Laboratories, UK) for 2 h, washed again with PBS and mounted in
VectorShield with DAPI (Vector Laboratories, UK). To assess macrophage
infiltration, fixed heart cryo-sections were permeabilized with 0.5% Triton
X-100 for 20 min, then blocked with 10% horse serum in PBS for 1 h prior
to incubation in 10% horse serum/PBS containing 1/100 rat anti-CD68
antibody (Abcam, UK) and 1/1000 WGA for 2 h. The sections were rinsed
twice with PBS, incubated with 1/1000 anti-rat IgG-FITC secondary
antibody (Abcam, UK) in 10% horse serum/PBS for 1 h, washed three
further times with PBS and mounted in VectorShield with DAPI. High-
resolution thin-section (0.5 µm) images were taken by confocal microscopy
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using a Zeiss LSM Axiovert 200M microscope fitted with a 63× water
objective, Zeiss LSM510 software and Adobe Photoshop CS. Images in
Fig. 1 were taken using a Zeiss AxioImager epifluorescence microscope
with AxioVision digital image processing software. CM cross-sectional area
counts were averaged from >four animals per group, five fields of view per
animal (40× objective) from healthy areas of the left ventricle.
Cell death
Click-iT TUNEL assay was performed to assess DNA fragmentation in
left-ventricular tissue according to the manufacturer’s instructions.
Briefly, heart cryo-sections were fixed in 4% paraformaldehyde and
permeabilized with 0.25% Triton X-100. 100 µl of TdT reaction buffer
was added to the sections for 10 min, followed by the TdT reaction
cocktail for 1 h at 37°C in a humidified chamber. The sections were
washed with 3% BSA and incubated in Click-iT reaction cocktail for
30 min. FITC-conjugated WGA was added for 2 h, followed by Hoechst
33342 (1/5000) for 15 min. The sections were mounted in VectorShield
and analysed by confocal microscopy as before. % TUNEL-positive CM
and NM cells were determined from a total of ten images (63×
magnification) per animal.
Detection of cells undergoing apoptosis was performed using Alexa-
Fluor-488-conjugated anti-cleaved caspase-3 (Cell Signaling Technology).
Heart cryo-sections were fixed in 4% paraformaldehyde for 20 min, then
permeabilized with 0.5% Triton X-100 for 20 min. The sections were
blocked with 5% normal goat’s serum for 1 h prior to overnight incubation
with anti-cleaved caspase-3 (1:50) in a humidified chamber at 4°C. The
heart sections were rinsed with PBS, and rhodamine-conjugated WGA
(1:2000) applied for 2 h. The sections were then rinsed with PBS (3×5 min),
andmounted in VectorShield with DAPI. The stainings were repeated twice,
on a total of nine individual sections per genotype.
For positive detection of cleaved caspase-3, mouse NIH3T3 fibroblasts
were treated with 1 µm staurosporine (Sigma) for 5 h at 37°C and the
staining was performed as described above. Fluorescent images were taken
with a Zeiss Axiovert microscope fitted with a 63× oil-immersion objective
and an AxioCam camera, using Openlab software with pre-determined
standardized settings (Improvision). Images were subsequently manipulated
using Adobe Photoshop to facilitate multicolour image overlay.
Statistical analysis
Data are presented as mean±s.e.m. Unless otherwise stated, data samples
were analysed by unpaired t-test using Graph Pad Prism v5.01 (GraphPad
Software Inc., USA). A value of P≤0.05 was considered significant.
(*P≤0.05, **P≤0.01 or ***P≤0.001).
Acknowledgements
We thank Drs A. Maqbool, S. Danby and D. Coverley for assistance and helpful
discussion.
Competing interests
The authors declare no competing or financial interests.
Author contributions
G.A.F. performed the experiments and analysed the data. M.J.D. performed the
functional assessment and contributed to interpretation of the data. N.A.T. and
S.G.B. provided intellectual input. J.F.X.A. conceived and designed the
experiments, and co-ordinated the project. G.A.F. and J.F.X.A. wrote the paper.
All authors commented on the paper.
Funding
This work was supported by the British Heart Foundation (PG/09/055).
Supplementary material
Supplementary material available online at
http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.019174/-/DC1
References
Ainscough, J. F. X., Drinkhill, M. J., Sedo, A., Turner, N. A., Brooke, D. A.,
Balmforth, A. J. and Ball, S. G. (2009). Angiotensin II type-1 receptor activation
in the adult heart causes blood pressure-independent hypertrophy and cardiac
dysfunction. Cardiovasc. Res. 81, 592-600.
Ballard, V. L. T., Sharma, A., Duignan, I., Holm, J. M., Chin, A., Choi, R., Hajjar,
K. A., Wong, S.-C. and Edelberg, J. M. (2006). Vascular tenascin-C regulates
cardiac endothelial phenotype and neovascularization. FASEB J. 20, 717.
Barrios, V., Calderón, A., Escobar, C., Barrios, S., Navarro-Cid, J., González-
Pedel, V., Vegazo, O. and Fernandez, R. (2007). Electrocardiographic left
ventricular hypertrophy regression induced by an angiotensin receptor blocker-
based regimen in daily clinical practice: the SARA study. J. Hypertens. 25,
1967-1973.
Berry, C., Touyz, R., Dominiczak, A. F., Webb, R. C. and Johns, D. G. (2001).
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with
ceramide. Am. J. Physiol. Heart Circ. Physiol. 281, H2337-H2365.
Birner, C. M., Ulucan, C., Fredersdorf, S., Rihm, M., Löwel, H., Stritzke, J.,
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